Safely culture and isolate micro-organisms of interest by following Good Laboratory Practices.
Accurately isolate microbial by-products using the microbiology laboratory manual.
Correctly process vaccines while adhering to Good Clinical Laboratory Practices (GCLP).
Safely perform laboratory animal vaccine trials following Good Clinical Laboratory Practices (GCLP).
These skills are essential because they help you create effective vaccines that protect health and save lives in the real world.
Developing simple vaccines is a critical skill for applied biology professionals working in Kenya's healthcare and research sectors. Vaccines provide an effective means of preventing infectious diseases that burden public health systems, especially in rural and underserved communities. This chapter explores fundamental laboratory techniques essential for vaccine development, focusing on culturing and isolating microorganisms, attenuation methods, and rigorous vaccine testing through animal models. The understanding gained here supports the design of safe and effective vaccines tailored to local disease challenges.
3.1 Culturing and Isolation of Microorganisms
Culturing and isolating microorganisms is a foundational step in vaccine development. It involves growing specific pathogens under controlled laboratory conditions to obtain pure cultures necessary for further manipulation, such as attenuation or antigen extraction. In Kenya, applied biology professionals working in county hospital laboratories or research institutes rely on these techniques to identify and prepare microbial strains for vaccine formulation. The precision and sterility in this process directly affect the safety and efficacy of the resulting vaccine.
Culturing Microorganisms for Vaccine Development
Culturing microorganisms requires creating an environment that supports the growth of the target pathogen while inhibiting contaminants. This is usually achieved by selecting appropriate culture media and incubation conditions that mimic the natural habitat of the microorganism.
Culture Media Selection
Nutrient-rich media encourage rapid growth, such as blood agar or nutrient broth, which provide essential vitamins, minerals, and growth factors for bacteria or viruses.
Selective media inhibit unwanted microbes, allowing isolation of specific pathogens; for example, MacConkey agar is used to select Gram-negative bacteria.
Differential media distinguish species by biochemical reactions, such as color changes indicating lactose fermentation.
Liquid media facilitate large-scale growth, essential for producing sufficient antigen quantities for vaccine preparation.
Solid media provide isolated colonies, enabling purity verification and isolation of single strains.
Incubation Conditions
Temperature control is critical; most human pathogens grow best at 37°C, reflecting human body temperature.
Oxygen requirements vary: aerobic microbes need oxygen, anaerobes require oxygen-free environments, and microaerophiles require reduced oxygen levels.
pH stability ensures optimal enzyme function and microbial metabolism, typically maintained between pH 6.8 and 7.4.
Incubation time must balance growth and viability, often ranging from 18 to 48 hours depending on the microorganism.
Humidity and light exposure can influence microbial growth and must be regulated accordingly.
Aseptic Techniques
Sterilization of media and equipment prevents contamination; autoclaving is standard for sterilizing culture media.
Using laminar flow cabinets minimizes airborne contaminants during inoculation.
Personal protective equipment (PPE) protects both the worker and culture from cross-contamination.
Proper disposal of used cultures follows biosafety protocols to prevent environmental release.
Routine decontamination of work surfaces with disinfectants like 70% ethanol maintains laboratory hygiene.
Isolation of Microorganisms
Isolating a pure culture from a mixed population is essential to ensure the vaccine targets a single pathogen strain, avoiding variability that could reduce effectiveness or safety.
Streak Plate Method
Dilutes the microbial sample across solid media to separate individual cells.
Allows growth of discrete colonies that can be picked for pure culture.
Requires sterile inoculating loops to prevent cross-contamination.
Involves multiple streaking quadrants to progressively reduce cell density.
Incubation follows to allow colony development visible to the naked eye.
Pour Plate and Spread Plate Techniques
Pour plate embeds microorganisms in molten agar, allowing growth inside the medium for quantification.
Spread plate spreads diluted samples on the agar surface, facilitating colony isolation.
Both methods enable estimation of viable cell counts, important for vaccine dose standardization.
Require serial dilution to reduce microbial density to countable levels.
Used to isolate colonies for further characterization and vaccine antigen extraction.
Biochemical and Molecular Identification
Biochemical tests confirm species based on metabolic traits, such as sugar fermentation or enzyme production.
Molecular techniques like PCR identify pathogens at the DNA level, ensuring strain accuracy.
Serological assays detect specific antigens or antibodies, verifying pathogen identity.
Accurate identification guides vaccine strain selection, crucial for targeting prevalent local pathogens.
Biosafety Considerations in Microbial Culturing and Isolation
Working with pathogenic microorganisms requires strict adherence to biosafety protocols to protect laboratory personnel and the environment.
Biosafety Levels (BSL)
BSL-1 applies to non-pathogenic strains, requiring standard microbiological practices.
BSL-2 handles moderate-risk agents like Salmonella, with additional PPE and restricted access.
BSL-3 is for airborne pathogens such as Mycobacterium tuberculosis, involving controlled airflow and specialized containment.
BSL-4 is reserved for high-risk agents with no cure, requiring full-body suits and isolated facilities.
Kenyan laboratories must comply with national biosafety regulations, often overseen by the Biosafety Authority.
Waste Disposal and Decontamination
All cultures and contaminated materials are autoclaved before disposal, preventing environmental contamination.
Liquid waste is treated with disinfectants such as bleach solutions prior to disposal.
Sharps are disposed of in puncture-proof containers, minimizing injury risk.
Regular cleaning of work surfaces with 70% ethanol or similar agents reduces contamination risk.
Incident reporting protocols ensure swift response to spills or exposures.
Decontamination Procedures
Decontamination is a critical process in laboratories to ensure that all surfaces, equipment, and materials are free from infectious agents before and after use. In Kenyan research institutions such as the Kenya Medical Research Institute (KEMRI), decontamination practices are strictly enforced to prevent laboratory-acquired infections and environmental contamination. The following are key decontamination procedures:
Routine cleaning of work surfaces with disinfectants: Surfaces are wiped with 70% ethanol or bleach solutions before and after experiments, and immediately after any spill, to eliminate pathogens.
Autoclaving reusable equipment: Autoclaves are used to sterilize glassware, pipette tips, and other reusable items at high pressure and temperature, ensuring all microorganisms are destroyed.
Decontamination of biological safety cabinets: After handling pathogens, cabinets are cleaned with appropriate disinfectants and sometimes exposed to UV light to inactivate residual microbes.
Use of chemical disinfectants for liquid waste: Waste liquids are treated with chemicals such as sodium hypochlorite before disposal, as required by institutional biosafety guidelines.
Regular maintenance and calibration of decontamination equipment: Laboratories keep logs for autoclave and disinfectant efficacy testing, as mandated by the Biosafety Act, to ensure ongoing effectiveness.
Practice Questions
Explain the importance of selective and differential media in isolating microorganisms for vaccine development. (6 marks)
Describe the steps involved in the streak plate method and its role in obtaining pure cultures. (8 marks)
Discuss the biosafety levels applicable in vaccine development laboratories and their significance. (6 marks)
3.1.1 Attenuation
Attenuation is a crucial process in vaccine development involving the reduction of a pathogen’s virulence while retaining its ability to induce an immune response. This technique produces live attenuated vaccines that provide strong and long-lasting immunity. In Kenya, attenuation methods are applied in research laboratories engaged in developing vaccines against diseases such as measles and tuberculosis. Understanding attenuation mechanisms ensures vaccines are both safe and effective for the population.
Principles of Attenuation
Attenuation reduces the disease-causing ability of the microorganism without eliminating its immunogenic properties.
Mechanisms of Attenuation
Genetic mutation through serial passage in non-human cells causes loss of virulence factors.
Temperature sensitivity induction restricts pathogen replication at human body temperature.
Chemical attenuation uses agents like formaldehyde to weaken pathogens.
Deletion of virulence genes via recombinant DNA technology creates safer vaccine strains.
Adaptation to unnatural environments reduces pathogenicity in humans while preserving antigenicity.
Goals of Attenuation
Maintain immunogenicity to stimulate strong immune memory.
Ensure safety by abolishing pathogenicity, preventing disease in vaccine recipients.
Achieve stability to avoid reversion to virulence during storage or administration.
Facilitate mass production of vaccine strains.
Provide broad protection against pathogen variants.
Methods of Attenuation
Different attenuation techniques are selected based on the pathogen type and vaccine requirements.
Serial Passage in Cell Culture
Repeatedly culturing the pathogen in non-human cells to induce mutations.
Alters surface proteins reducing virulence in humans.
Common for viruses such as measles and rubella.
Requires careful monitoring to prevent complete loss of immunogenicity.
Relies on cell lines like Vero or chicken embryo fibroblasts.
Temperature Sensitivity
Pathogens are adapted to grow at lower temperatures.
They cannot replicate efficiently at 37°C in humans.
Used in vaccines like the cold-adapted influenza vaccine.
Enhances safety by limiting pathogen spread in the host.
Requires validation of attenuation stability.
Chemical Attenuation
Exposure to chemicals such as formaldehyde or β-propiolactone inactivates virulence factors.
Common in inactivated vaccines but can be used to attenuate live vaccines.
Must be carefully controlled to avoid destroying immunogenic epitopes.
Widely used in bacterial vaccines like the pertussis vaccine.
Chemical residues must be removed to prevent toxicity.
Genetic Engineering
Targeted deletion or modification of virulence genes.
Enables development of vaccines for complex pathogens.
Requires advanced laboratory facilities and regulatory approval.
Example: genetically attenuated malaria vaccines in research.
Challenges and Safety Measures in Attenuation
Attenuation must balance immune protection with safety to avoid causing disease.
Challenges in Attenuation
Risk of reversion to virulence, leading to vaccine-associated infections.
Maintaining immunogenicity while reducing pathogenicity can be difficult.
Ensuring genetic stability over multiple passages.
Scalability of attenuation methods for mass production.
Regulatory hurdles and public acceptance.
Safety Measures
Extensive in vitro and in vivo testing for virulence.
Genetic characterization to detect mutations and stability.
Use of multiple attenuation methods to reduce reversion risk.
Strict manufacturing controls following Good Manufacturing Practices (GMP).
Post-marketing surveillance for adverse events.
Practice Questions
Outline the different methods of attenuation used in vaccine development and their mechanisms. (10 marks)
Discuss the importance of genetic stability in attenuated vaccines and how it is ensured. (6 marks)
Identify challenges faced during attenuation and the safety measures applied to address them. (8 marks)
3.1.2 Testing Vaccines Using Animal Models
Selection of Animal Models for Vaccine Testing
Choosing an appropriate animal model depends on the pathogen, vaccine type, and study objectives.
Criteria for Model Selection
Physiological similarity to humans ensures relevant immune responses.
Susceptibility to the pathogen allows infection and assessment of protection.
Cost and availability of animals influence feasibility in Kenyan research settings.
Ethical considerations and regulatory approval guide model use.
Reproducibility and ease of handling facilitate consistent results.
Common Animal Models
Mice: widely used for initial safety and immunogenicity studies due to low cost and genetic tools.
Rabbits: useful for antibody production and toxicity testing.
Guinea pigs: employed in tuberculosis vaccine studies for respiratory infection modeling.
Non-human primates: closely mimic human immune responses but are expensive and require high biosafety.
Zebrafish and other alternative models emerging for specific vaccine research.
Procedures for Vaccine Testing in Animals
Testing vaccines involves several key procedures to evaluate their performance.
Immunization Protocols
Determining dose and route of administration (e.g., intramuscular, subcutaneous).
Scheduling primary and booster doses to mimic human vaccination regimens.
Monitoring animals for clinical signs and adverse effects.
Collecting blood samples for immunological assays.
Recording weight and behavior changes as safety indicators.
Immunogenicity Assessment
Measuring antibody titers using ELISA or neutralization assays.
Evaluating cell-mediated immunity via lymphocyte proliferation or cytokine profiling.
Assessing duration of immune response over time.
Comparing responses to control and placebo groups.
Analyzing correlates of protection relevant to the disease.
Challenge Studies
Exposing vaccinated and control animals to the live pathogen under controlled conditions.
Monitoring for infection signs, pathogen load, and survival rates.
Determining vaccine efficacy based on protection levels.
Ensuring humane endpoints to minimize animal suffering.
Performing necropsies for pathological examination.
Ethical Considerations and Regulatory Compliance
Ethical standards govern animal use in vaccine research to ensure humane treatment and scientific integrity.
Ethical Principles
Replacement: use alternative methods when possible.
Reduction: minimize animal numbers without compromising data quality.
Refinement: optimize procedures to reduce pain and distress.
Justification of animal use based on scientific necessity.
Obtaining approval from institutional animal care and use committees.
Regulatory Framework in Kenya
Adherence to the Kenya Veterinary Board and National Council for Science, Technology and Innovation (NACOSTI) guidelines.
Compliance with international standards such as the Animal Welfare Act.
Regular inspections of animal facilities for welfare and biosafety.
Training of personnel in ethical handling and care of animals.
Documentation and reporting of all animal experiments.
Practice Questions
Explain the criteria for selecting animal models in vaccine testing and provide examples relevant to Kenyan research. (8 marks)
Describe the procedures involved in immunogenicity assessment during vaccine testing in animals. (8 marks)
Discuss the ethical principles and regulatory requirements governing animal use in vaccine development. (6 marks)
3.1.3 Vaccine Trials
Presenting vaccine trial data clearly and accurately is vital for scientific communication, regulatory review, and public trust. In Kenya, professionals involved in vaccine development must prepare comprehensive reports and presentations for stakeholders including regulatory bodies, funding agencies, and the scientific community. Effective presentation integrates statistical analysis, visual aids, and narrative explanations to convey trial outcomes.
Components of Vaccine Trial Reports
Vaccine trial reports document the methodology, results, and interpretations of vaccine testing phases.
Essential Sections
Introduction outlining the vaccine candidate and study objectives.
Materials and methods detailing experimental design, animal models, and procedures.
Results presenting immunogenicity, safety, and efficacy data with statistical analyses.
Discussion interpreting findings in the context of existing research and limitations.
Conclusion summarizing implications and recommendations for further development.
Data Presentation
Use of tables to summarize quantitative data such as antibody titers and infection rates.
Graphs and charts illustrating trends over time or between groups.
Photographic evidence of pathological findings or clinical signs.
Clear labeling and legends for all figures.
Inclusion of raw data in appendices for transparency.
Oral Presentation of Vaccine Trial Findings
Oral presentations require clarity, engagement, and the ability to answer questions effectively.
Preparation and Structure
Organize content logically starting with background and moving to results.
Highlight key findings with visuals such as slides or posters.
Practice concise explanations avoiding jargon for mixed audiences.
Prepare to address potential questions on methodology and data interpretation.
Use real-world implications to connect with stakeholders’ interests.
Communication Techniques
Maintain eye contact and use clear voice projection.
Employ body language to emphasize important points.
Use analogies or examples to clarify complex concepts.
Manage time effectively to cover all topics.
Encourage audience interaction and feedback.
Reporting to Regulatory Authorities and Stakeholders
Regulatory submissions require adherence to standards and comprehensive documentation.
Regulatory Requirements
Follow guidelines from the Pharmacy and Poisons Board of Kenya for vaccine approval.
Include data on safety, efficacy, manufacturing, and quality control.
Provide detailed protocols and ethical approvals.
Submit adverse event reports and risk assessments.
Maintain communication during review and respond promptly to queries.
Stakeholder Engagement
Present findings to funding agencies to secure continued support.
Communicate with healthcare providers to prepare for vaccine rollout.
Engage community leaders to build public trust and acceptance.
Disseminate results through scientific publications and conferences.
Utilize media responsibly to inform the public without causing undue alarm.
Practice Questions
List and explain the key components that must be included in a vaccine trial report. (10 marks)
Discuss strategies for effective oral presentation of vaccine trial data to diverse audiences. (6 marks)
Describe the regulatory requirements for vaccine trial reporting in Kenya. (6 marks)
Chapter Summary
This chapter explored the process of developing simple vaccines, beginning with the culturing and isolation of microorganisms, which is fundamental for obtaining pure strains necessary for vaccine production. It then examined attenuation, a critical step that involves weakening the pathogen to ensure it stimulates an immune response without causing disease. The chapter proceeded to discuss the use of animal models in testing vaccines, highlighting their role in evaluating safety and efficacy before human application. Finally, it covered the presentation of vaccine trials, emphasizing the importance of systematic documentation and analysis to meet regulatory standards and inform further development. Together, these topics provide a comprehensive overview of the initial stages of vaccine development from laboratory preparation to preliminary testing and evaluation.
Define attenuation in the context of vaccine development. (2 marks)
Describe two methods commonly used to attenuate microorganisms for vaccines. (4 marks)
Explain why animal models are essential in testing vaccines before human trials. (3 marks)
List three characteristics that an ideal animal model should have for vaccine testing. (3 marks)
What are the main phases of vaccine trials presentation? Provide a brief description of each. (6 marks)
Describe the role of culturing microorganisms in the development of vaccines. (3 marks)
Identify two ethical considerations when using animal models in vaccine testing. (4 marks)
Explain the difference between live attenuated vaccines and inactivated vaccines. (3 marks)
Outline the steps involved in isolating microorganisms from a clinical sample for vaccine development. (4 marks)
Discuss the importance of rigorous vaccine trials presentation to regulatory bodies in Kenya. (3 marks)
Show Answers
Attenuation is the process of reducing the virulence of a microorganism so that it can stimulate an immune response without causing disease. It is a key step in developing live vaccines.
Two common attenuation methods are:
Serial passage in non-human cells, which weakens the pathogen by adapting it to grow in different environments.
Exposure to chemicals or heat that reduce pathogenicity while maintaining antigenicity.
Animal models provide a living system to evaluate vaccine safety, immunogenicity, and efficacy before human use, helping to identify potential adverse effects and immune responses.
Characteristics include:
Similar immune system to humans to predict vaccine response.
Susceptibility to the pathogen under study.
Ability to reproduce disease symptoms seen in humans.
Main phases of vaccine trials presentation are:
Preclinical phase: data from laboratory and animal studies.
Clinical phase: results from human trials (Phase I, II, III).
Regulatory submission: compilation and presentation of data for approval.
Culturing microorganisms allows for the growth and multiplication of pathogens under controlled conditions to obtain sufficient quantities for attenuation and vaccine formulation.
Ethical considerations include:
Minimizing animal suffering through humane treatment and care.
Justifying the use of animals only when no alternative methods exist.
Live attenuated vaccines contain weakened but live pathogens capable of replication, whereas inactivated vaccines contain killed pathogens that cannot replicate but still provoke immune responses.
Steps in isolating microorganisms include:
Collecting a sterile clinical sample.
Inoculating the sample onto selective culture media.
Incubating under appropriate conditions.
Identifying and purifying the colonies for further use.
Vaccine trials presentation to Kenyan regulatory bodies like the Pharmacy and Poisons Board ensures vaccines meet safety, quality, and efficacy standards before public use, protecting public health.
B. Oral Assessment
Discuss the challenges and ethical considerations involved in using animal models for vaccine testing in Kenyan research institutions.
Explain how attenuation techniques can influence the effectiveness and safety of vaccines developed for diseases prevalent in Kenya.
Answer Guide
Question 1 key points:
Ethical concerns about animal welfare and the necessity to minimize suffering.
Challenges in selecting appropriate animal models that accurately mimic human disease.
Regulatory requirements and public scrutiny in Kenya regarding animal testing.
Balancing scientific benefits against ethical costs.
Question 2 key points:
Attenuation must reduce virulence without compromising immunogenicity to ensure safety and efficacy.
Techniques like serial passage can alter antigenic properties impacting vaccine performance.
Local pathogen strains may require specific attenuation approaches for effectiveness against Kenyan disease variants.
The Kenya Medical Research Institute (KEMRI) is developing a new vaccine against Rift Valley Fever virus, which involves culturing the virus, attenuation, and testing in animal models before human trials.
Tasks:
a) Outline the laboratory procedures KEMRI scientists would follow to culture and isolate the Rift Valley Fever virus for vaccine development. (6 marks)
b) Describe how KEMRI might perform attenuation of the virus and the criteria to confirm successful attenuation. (6 marks)
c) Explain the steps involved in preparing a vaccine trials presentation for submission to the Pharmacy and Poisons Board in Kenya. (8 marks)
Suggested Approach
a) Procedures include collecting infected samples, inoculating them into suitable cell cultures or embryonated eggs, incubating under controlled conditions, monitoring for cytopathic effects, and isolating pure viral cultures through plaque assays or limiting dilution.
b) Attenuation could be done by serial passage in non-human cells or exposure to chemical agents; success is confirmed by reduced virulence in animal models while maintaining immunogenicity, demonstrated by safety and protective immune response.
c) Steps for trials presentation involve compiling preclinical data, detailing animal model testing outcomes, presenting clinical trial protocols and results, demonstrating adherence to ethical and regulatory guidelines, and submitting comprehensive documentation to the Pharmacy and Poisons Board for review and approval.
Chapter Examination Questions
🔒 PDFDownload these examination questions, with worked answers
SECTION A (40 Marks) - Answer ALL Questions
Explain the process of attenuation of microorganisms in the development of vaccines and its significance in vaccine safety. (4 marks)
Describe how animal models are used in testing vaccines and give one example of a commonly used animal in Kenya for this purpose. (4 marks)
List four key criteria that must be evaluated during vaccine trials before approval for human use. (4 marks)
Outline the steps involved in the culturing and isolation of microorganisms for vaccine development in a laboratory setting. (4 marks)
Discuss the ethical considerations that must be observed when using animal models for vaccine testing. (4 marks)
Identify and explain two methods used to confirm the attenuation of a pathogenic microorganism. (4 marks)
Explain why vaccine trials are usually conducted in phases and what is the main focus of each phase. (4 marks)
Describe the role of a county public health laboratory in Kenya during vaccine trials. (4 marks)
Explain how the sterility of a vaccine batch is tested during vaccine production. (4 marks)
Discuss the importance of proper documentation and presentation of vaccine trial results to regulatory bodies like the Pharmacy and Poisons Board in Kenya. (4 marks)
Section A - Answers
Attenuation involves weakening a microorganism so it loses its virulence but retains the ability to induce immunity. This ensures the vaccine is safe and does not cause disease in recipients.
Animal models are used to evaluate the safety and efficacy of vaccines before human trials. For example, mice are commonly used for preliminary testing in Kenyan laboratories.
Criteria include safety, immunogenicity, dosage, and side effects monitoring.
Steps include sample collection, inoculation on selective media, incubation under controlled conditions, isolation of pure colonies, and identification of microorganisms.
Ethical considerations include minimizing animal suffering, using the least number of animals necessary, and obtaining approval from an ethical review committee.
Methods include observing loss of pathogenicity in animal models and genetic analysis showing mutation or deletion of virulence genes.
Phases include Phase I (safety and dosage), Phase II (efficacy and side effects), and Phase III (large scale efficacy and monitoring adverse reactions).
A county public health laboratory conducts sample analysis, monitors adverse events, and supports data collection during vaccine trials.
Sterility tests involve culturing vaccine samples in nutrient media to detect contamination by bacteria or fungi.
Proper documentation ensures transparency, facilitates regulatory approval, and helps maintain public trust in vaccines.
SECTION B (60 Marks) - Answer any TWO Questions
Question 11 (Compulsory - 20 marks)
The Kenya Medical Research Institute (KEMRI) is developing a new vaccine against Rift Valley Fever. They have successfully attenuated the virus and are preparing for animal trials.
a) Explain the procedures KEMRI would use to confirm that the virus has been adequately attenuated before proceeding to animal testing. (10 marks)
b) Discuss how KEMRI should conduct and document the vaccine trials using animal models to meet national regulatory standards. (10 marks)
Question 12 (20 marks)
Describe the phases of vaccine trials and explain the importance of each phase in ensuring vaccine efficacy and safety, using examples relevant to vaccines developed for livestock diseases in Kenya.
Question 13 (20 marks)
Explain the ethical implications and regulatory requirements involved in culturing and isolating microorganisms for vaccine development in Kenya, including the role of institutional review boards.
Question 14 (20 marks)
Outline the key elements that should be included in a vaccine trial presentation report submitted to the Pharmacy and Poisons Board in Kenya, emphasizing how clarity and thoroughness support the approval process.
Section B - Answers
Question 11
a) Confirmation of attenuation involves several steps: repeated culturing of the virus under specific conditions to reduce virulence, followed by testing on susceptible animal models to observe if the virus causes disease. Genetic sequencing may also be used to detect mutations associated with attenuation. These procedures ensure the virus cannot revert to a pathogenic form.
b) KEMRI should follow a structured protocol including selecting appropriate animal models, administering the vaccine under controlled conditions, monitoring animals for immune response and adverse effects, and maintaining detailed records. Ethical approval must be obtained, and all procedures documented in compliance with the Kenya Pharmacy and Poisons Board guidelines. Data should be analyzed statistically and presented clearly for regulatory review.
Question 12
Vaccine trials proceed in phases: Phase I tests safety and dosage in a small group; Phase II assesses efficacy and side effects in a larger population; Phase III involves large scale testing to confirm effectiveness and monitor rare adverse events. For livestock vaccines, such as those for East Coast Fever, these phases ensure the vaccine is safe for animals, provides adequate immunity, and can be produced consistently. Each phase protects animal health and supports regulatory approval.
Question 13
Ethical implications include ensuring biosafety, preventing environmental contamination, and protecting human handlers. Regulatory requirements mandate adherence to the Biosafety Act and obtaining clearance from institutional review boards. These boards assess risk, monitor compliance, and ensure that culturing of pathogens is done responsibly to avoid accidental release or misuse. Proper training and containment facilities are essential.
Question 14
A vaccine trial report should include the trial objectives, methodology (including animal models used), data on safety and efficacy, adverse event monitoring, statistical analysis, and conclusions. It must demonstrate compliance with ethical and regulatory standards. Clear presentation of results, supported by graphs and tables, facilitates decision-making by the Pharmacy and Poisons Board. Transparency in data handling and documentation is critical for approval.
